Cerenis Series C swells to €50M; Dicerna adds $4M to second round; Biotech vet takes helm at Transdel;

 @FierceBiotech: Amylin shares crater after FDA rejects Bydureon app. News | Follow @FierceBiotech

 @JohnCFierce: I used to think the FDA was just getting a bit tougher. Now I wonder if it's becoming excessively cautious. Anyone have thoughts on that? | Follow @JohnCFierce

Special Report: Pharma manufacturing consent decrees: 16 black holes. Report

> Cerenis Therapeutics, which has operations in France and Ann Arbor, has added €10 million to its Series C, bringing the total to € 50 million. The latest €10 million came from the group IRDI-IXO and undisclosed international private investors. Cerenis release

> A flu vaccine made using dog kidney cells appears to be as safe and effective as one produced using chicken eggs--the traditional but slower method, according to a study. Report

> With its slumping share price revived by persistent rumors of a possible takeover, Actelion announced plans to buy back up to $827 million shares in the next three years. The Swiss biotech insists that it also wants to remain independent, but that hasn't blunted investors' enthusiasm for a deal. Story

> Novartis CEO Joe Jimenez says that the Big Pharma company has already begun to work with Alcon at "arms length," rather than wait to complete the acquisition of all the remaining shares in the company. Novartis owns 77 percent of the company now. Story

> Dicerna Pharmaceuticals announced a second closing of its Series B, raising an additional $4 million and bringing the total capital raised in this round to $29 million. Glaxo's SR One joins the existing investor syndicate, which includes Oxford Bioscience Partners, Skyline Ventures, Abingworth and Domain Associates. Dicerna release

> John Bonfiglio, the former CEO at Argos Therapeutics, has been named CEO of Transdel Pharmaceuticals in La Jolla, CA. Transdel release

> Genzyme's cancer drug Clolar failed a late-stage AML study. Investigators combined Clolar with the chemo drug cytarabine and compared it against cytarabine alone. Report

And Finally... Motherhood may actually cause the brain to grow, not turn it into mush, as some have claimed. Release

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.